Kowa Research Institute based in Morrisville, NC and Kowa Pharmaceuticals America, Inc., a privately-held specialty pharmaceutical company headquartered in Montgomery, AL, announced today that the U.S. FDA has approved LIVALO (pitavastatin), a potent HMG-CoA reductase inhibitor (statin), for the primary treatment of hypercholesterolemia and combined dyslipidemia.
the details can be read here.
No comments:
Post a Comment